Prospective Comparison of Flecainide Versus Sotalol for Immediate Cardioversion of Atrial Fibrillation

Reisinger, J.; Gatterer, Edmund; Heinze, Georg; Wiesinger, K; Zeindlhofer, E.; Gattermeier, Martin; Poelzl, Gerhard; Krätzer, H; Ebner, Anton; Hohenwallner, W; Lenz, Kurt; Slaný, J; Kühn, Peter

doi:10.1016/s0002-9149(98)00223-9

Cited by 105 publications

(53 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…596 Both amiodarone and flecainide appear more effective than sotalol in restoring sinus rhythm. 600,601,619 11.1.2 'Pill in the pocket' cardioversion performed by patients In selected patients with infrequent symptomatic episodes of paroxysmal AF, a single bolus of oral flecainide (200-300 mg) or propafenone (450-600 mg) can be self-administered by the patient at home ('pill in the pocket' therapy) to restore sinus rhythm, after safety has been established in the hospital setting. 620 This approach seems marginally less effective than hospital-based cardioversion, 621 but is practical and provides control and reassurance to selected patients.…”

Section: Rhythm Control Therapy In Atrial Fibrillationmentioning

confidence: 99%

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof¹,

Benussi²,

Kotecha³

et al. 2016

Eur J Cardiothorac Surg

915

625

View full text Add to dashboard Cite

Section: Rhythm Control Therapy In Atrial Fibrillationmentioning

confidence: 99%

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof¹,

Benussi²,

Kotecha³

et al. 2016

Eur J Cardiothorac Surg

915

625

View full text Add to dashboard Cite

“…harmacological termination of atrial fibrillation (AF) lasting more than 1 week is usually considered difficult, 1 but we have demonstrated that oral administration of bepridil alone or in combination with aprindine can restore sinus rhythm (SR) in nearly 70% patients with long-lasting persistent AF (AF >1 month), 2 because bepridil suppresses the mechanisms of maintaining persistent AF. 3 Some cases of persistent AF may be preceded by episodes of paroxysmal AF (PAF).…”

mentioning

confidence: 99%

Pharmacological Cardioversion of Persistent Atrial Fibrillation With and Without a History of Drug-Resistant Paroxysmal Atrial Fibrillation

Fujiki

Sakamoto

Iwamoto

et al. 2006

Circ J

View full text Add to dashboard Cite

“…Of the 962 patients included in the study, one patient was known to develop TdP after receiving IV sotalol 35 ; a 62-year-old woman with a prior anterior MI presented with atrial fibrillation and a mean ventricular rate of 100 beats/min. The patient had normal renal function with normal plasma potassium and magnesium, and the QT interval was 360 msec.…”

Section: 51mentioning

confidence: 99%

“…Of the patients included in the analysis, asymptomatic hypotension was reported in five, 35 and 13 had hypotension with uncertain symptomatology. 7,32,43 Five patients experienced symptomatic hypotension or presyncope that did not necessitate specific treatment.…”

Section: 51mentioning

confidence: 99%

See 1 more Smart Citation

Meta‐analysis of the Risk of Torsades de Pointes in Patients Treated with Intravenous Racemic Sotalol

Marill

Runge

2001

Academic Emergency Medicine

View full text Add to dashboard Cite

Abstract. Objective: Intravenous (IV) racemic sotalol is useful for the treatment of multiple tachydysrhythmias. The authors hypothesized that the risk of torsades de pointes (TdP) in patients treated with a single IV infusion of sotalol is lower than the 2-4% risk associated with chronic oral sotalol therapy. Methods: A MEDLINE search under the subject heading ''sotalol'' was made of all publications involving humans written in English or German from 1966 to October 1, 2000. A meta-analysis of all original reports including patients who were given a single infusion of at least 1.5 mg/kg or 100 mg of IV sotalol over 30 minutes or less was performed. Potential variables predictive of TdP were assessed. The primary outcome was the observation of TdP associated with IV sotalol infusion. Secondary measurements included hypotension, bradycardia, and worsening of congestive heart failure. All excluded studies and case reports were also examined for evidence of TdP associated with IV sotalol treatment. Results: The search included 1,005 publications. There were 37 reports in which 962 patients received IV sotalol and met the inclusion criteria. There was one report of self-terminating TdP lasting 10 seconds among the 962 patients included in the study. There was no report of TdP associated with only IV racemic sotalol administration in any of the excluded studies. If it is assumed that the risk of TdP is homogeneous in the population of patients treated with IV sotalol, then based on the 962 included patients, the rate of TdP is 0.1% (95% CI = 0.003% to 0.6%). Conclusions: The overall risk of TdP in patients treated with a single infusion of IV sotalol is low compared with that in patients given chronic oral sotalol therapy.

show abstract

Prospective Comparison of Flecainide Versus Sotalol for Immediate Cardioversion of Atrial Fibrillation

Cited by 105 publications

References 25 publications

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Pharmacological Cardioversion of Persistent Atrial Fibrillation With and Without a History of Drug-Resistant Paroxysmal Atrial Fibrillation

Meta‐analysis of the Risk of Torsades de Pointes in Patients Treated with Intravenous Racemic Sotalol

Contact Info

Product

Resources

About